Media Coverage: Clinical trials are neither last chance saloon nor guinea pig experiments

Adj A/Prof Danny Soon, Chief Executive Officer, CRIS and Executive Director, SCRI highlights in this commentary that Singapore’s multi-ethnic population presents a valuable opportunity to increase Asian representation in global clinical trials. This ensures treatments are safe and effective across diverse patient cohorts. Singapore-anchored clinical trials can therefore play a crucial role in developing novel treatments that are safer, more effective and more equitable.

He emphasises that clinical trials undergo robust review and stringent regulatory oversight before approval with patient safety and well-being maintained throughout the study.

Looking ahead, he writes that clinical trials can be introduced early in the care journey, and discussed as a clinical care option where appropriate, and not necessarily as a last resort.

The full commentary is available on The Straits Times. ↗ (opens in new tab)